Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Vaira

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
BMC Surgery|July 19, 2020
Indocyanine green fluorescence-guided intraoperative detection of peritoneal carcinomatosis: systematic reviewGian Luca Baiocchi, Federico Gheza, Sarah Molfino, et al.
International Journal of Environmental Research and Public Health|June 2, 2021
Study Protocol: Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal MetastasesManuela Robella, Paola Berchialla, Alice Borsano, et al.
In Vivo (Athens, Greece)|February 6, 2010
Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten yearsMarco Vaira, Tommaso Cioppa, Silvia D'Amico, et al.
Frontiers in Pharmacology|July 12, 2019
Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx<sup>®</sup>) as Pressurized Intraperitoneal Aerosol ChemotherapyManuela Robella, Marco Vaira, Monica Argenziano, et al.
In Vivo (Athens, Greece)|July 2, 2009
Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experienceMarco Vaira, Tommaso Cioppa, Giovanni DE Marco, et al.
Biomedicines|May 6, 2020
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical TrialMichele De Simone, Marco Vaira, Monica Argenziano, et al.
Pleura and Peritoneum|March 27, 2019
Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane™) for peritoneal carcinomatosis - a phase I first-in-human studyLeen Van De Sande, Martin Graversen, Martin Hubner, et al.
Journal of Surgical Oncology|February 1, 2003
Semi-closed hyperthermic-antiblastic peritoneal perfusion (HAPP) in the treatment of peritoneal carcinosisMichele De Simone, Riccardo Barone, Marco Vaira, et al.
Journal of Surgical Oncology|September 19, 2019
Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPECDaniele Biacchi, Fabio Accarpio, Luca Ansaloni, et al.
Cancers|April 3, 2021
A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal CarcinomatosisManuela Robella, Michele De Simone, Paola Berchialla, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
BMC Surgery|July 19, 2020
Indocyanine green fluorescence-guided intraoperative detection of peritoneal carcinomatosis: systematic reviewGian Luca Baiocchi, Federico Gheza, Sarah Molfino, et al.
International Journal of Environmental Research and Public Health|June 2, 2021
Study Protocol: Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal MetastasesManuela Robella, Paola Berchialla, Alice Borsano, et al.
In Vivo (Athens, Greece)|February 6, 2010
Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten yearsMarco Vaira, Tommaso Cioppa, Silvia D'Amico, et al.
Frontiers in Pharmacology|July 12, 2019
Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx<sup>®</sup>) as Pressurized Intraperitoneal Aerosol ChemotherapyManuela Robella, Marco Vaira, Monica Argenziano, et al.
In Vivo (Athens, Greece)|July 2, 2009
Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experienceMarco Vaira, Tommaso Cioppa, Giovanni DE Marco, et al.
Biomedicines|May 6, 2020
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical TrialMichele De Simone, Marco Vaira, Monica Argenziano, et al.
Pleura and Peritoneum|March 27, 2019
Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane™) for peritoneal carcinomatosis - a phase I first-in-human studyLeen Van De Sande, Martin Graversen, Martin Hubner, et al.
Journal of Surgical Oncology|February 1, 2003
Semi-closed hyperthermic-antiblastic peritoneal perfusion (HAPP) in the treatment of peritoneal carcinosisMichele De Simone, Riccardo Barone, Marco Vaira, et al.
Journal of Surgical Oncology|September 19, 2019
Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPECDaniele Biacchi, Fabio Accarpio, Luca Ansaloni, et al.
Cancers|April 3, 2021
A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal CarcinomatosisManuela Robella, Michele De Simone, Paola Berchialla, et al.
Pageof 5